Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Digitizing the Industry

PV0315_TarenGromIn this month’s Forum, we explore the opportunities, challenges, and  processes involved in the industry’s transformation into the digital age. For most of us, digital technologies have become part of our every day life, yet many pharmaceutical companies are still navigating through their complex business models, many of which are still siloed and not conducive to digital breakthroughs.

In a jointly conducted survey by Arthur D. Little and Karlsruher Institute of Technology, the results show that although many companies have not yet formulated a concise digital health strategy, industry executives expect that by 2020, digital health will enable pharmaceutical companies to activate new business segments as well as to significantly improve their competitive advantage. Within the context of the survey, digital health represents the convergence of digital technologies (especially information and communication technologies and data analytics) with elements and decision-making structures of the traditional care value chain. The study results indicate that by 2020 the business model of the pharmaceutical industry will be reshaped by digital health:
• 84% of study participants consider it crucial to have a digital health strategy in 2020, compared with 13% who believe it is already crucial today;
• Whereas digital health programs are today still in an evaluation and piloting phase, 73% of participants are sure these programs will be implemented by 2020;
• 77% believe digital health will generate new business by 2020, and 94% believe it will either extend the existing value proposition (37%) or even invent a new value proposition for the pharmaceutical industry (57%); and
• Consequently, all participants believe digital health will have an important (27%) or even crucial impact (73%) for the competitive advantage of their pharmaceutical companies.

Over the next decade, these analysts believe that the transformation realized in the recent past will be even more dramatic, resulting from factors such as advances in genetic, cell, and tissue techniques; interventional medical technologies; neuro-engineering; intelligent prosthetics; and improved imaging technologies. They predict that digital health applications in integrated healthcare offerings and information and communication technologies, which can tap into the full potential of big data analytics, will transform the way healthcare is perceived.

According to a recent Accenture report, there are five digital trends that are significantly influencing the industry: the Internet of Me, or  personalized healthcare; outcome economy, hardware producing health results; the platform revolution which is defining ecosystems; intelligence enterprise, a data explosion; and a re-imagined workforce, the  collaboration at the intersection of humans and healthcare.

Digital is, and will continue transforming the healthcare industry and we look forward to following the revolution.

Taren Grom
Editor

~~~~~~~~~~~~~~~~~~~~~~~~~

Their word…PV0316_TheirWord

Denise Myshko
Managing Editor

The human microbiome has a much larger impact on our health than we realize.

Robin Robinson
Senior Editor

The industry has begun to digitize parts of its organizational functions, but within a few years, it could be forced to transform these into completely digital-enabled enterprises.

Kim Ribbink
Features Editor

Despite economic challenges there is general optimism about growth prospects for Russia’s pharmaceutical industry.

~~~~~~~~~~~~~~~~~~~~~~~~~

Masthead

Volume 16 • Number 3
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2016
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Sixteen, Number Three

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

 

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK